177 related articles for article (PubMed ID: 21453270)
1. Comparison of cytochrome P450 2D6 and variants in terms of drug oxidation rates and substrate inhibition.
Niwa T; Murayama N; Yamazaki H
Curr Drug Metab; 2011 Jun; 12(5):412-35. PubMed ID: 21453270
[TBL] [Abstract][Full Text] [Related]
2. Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6.
Niwa T; Hiroi T; Tsuzuki D; Yamamoto S; Narimatsu S; Fukuda T; Azuma J; Funae Y
Brain Res Mol Brain Res; 2004 Oct; 129(1-2):117-23. PubMed ID: 15469888
[TBL] [Abstract][Full Text] [Related]
3. Functional evaluation of cytochrome P450 2D6 with Gly42Arg substitution expressed in Saccharomyces cerevisiae.
Tsuzuki D; Takemi C; Yamamoto S; Tamagake K; Imaoka S; Funae Y; Kataoka H; Shinoda S; Narimatsu S
Pharmacogenetics; 2001 Nov; 11(8):709-18. PubMed ID: 11692080
[TBL] [Abstract][Full Text] [Related]
4. Functional and structural characterisation of common cytochrome P450 2D6 allelic variants-roles of Pro34 and Thr107 in catalysis and inhibition.
Dong AN; Ahemad N; Pan Y; Palanisamy UD; Yiap BC; Ong CE
Naunyn Schmiedebergs Arch Pharmacol; 2019 Aug; 392(8):1015-1029. PubMed ID: 31025144
[TBL] [Abstract][Full Text] [Related]
5. Stereoselectivity of human cytochrome p450 in metabolic and inhibitory activities.
Niwa T; Murayama N; Yamazaki H
Curr Drug Metab; 2011 Jul; 12(6):549-69. PubMed ID: 21476971
[TBL] [Abstract][Full Text] [Related]
6. Role of P34S, G169R, R296C, and S486T Substitutions in Ligand Access and Catalysis for Cytochrome P450 2D6 Allelic Variants CYP2D6*14A and CYP2D6*14B.
Dong AN; Ahemad N; Pan Y; Palanisamy UD; Yiap BC; Ong CE
Drug Metab Bioanal Lett; 2022; 15(1):51-63. PubMed ID: 35049443
[TBL] [Abstract][Full Text] [Related]
7. Functional influence of human CYP2D6 allelic variations: P34S, E418K, S486T, and R296C.
Kim J; Lim YR; Han S; Han JS; Chun YJ; Yun CH; Lee CH; Kim D
Arch Pharm Res; 2013 Dec; 36(12):1500-6. PubMed ID: 23897164
[TBL] [Abstract][Full Text] [Related]
8. A combination of mutations in the CYP2D6*17 (CYP2D6Z) allele causes alterations in enzyme function.
Oscarson M; Hidestrand M; Johansson I; Ingelman-Sundberg M
Mol Pharmacol; 1997 Dec; 52(6):1034-40. PubMed ID: 9415713
[TBL] [Abstract][Full Text] [Related]
9. Comparison of cytochrome P450 2C subfamily members in terms of drug oxidation rates and substrate inhibition.
Niwa T; Yamazaki H
Curr Drug Metab; 2012 Oct; 13(8):1145-59. PubMed ID: 22571484
[TBL] [Abstract][Full Text] [Related]
10. The gastroprokinetic and antiemetic drug metoclopramide is a substrate and inhibitor of cytochrome P450 2D6.
Desta Z; Wu GM; Morocho AM; Flockhart DA
Drug Metab Dispos; 2002 Mar; 30(3):336-43. PubMed ID: 11854155
[TBL] [Abstract][Full Text] [Related]
11. Effects of G169R and P34S substitutions produced by mutations of CYP2D6*14 on the functional properties of CYP2D6 expressed in V79 cells.
Shiraishi T; Hosokawa M; Kobayashi K; Tainaka H; Yamaura Y; Taguchi M; Chiba K
Drug Metab Dispos; 2002 Nov; 30(11):1201-5. PubMed ID: 12386125
[TBL] [Abstract][Full Text] [Related]
12. Characterization of cytochrome P450 2D6.1 (CYP2D6.1), CYP2D6.2, and CYP2D6.17 activities toward model CYP2D6 substrates dextromethorphan, bufuralol, and debrisoquine.
Marcucci KA; Pearce RE; Crespi C; Steimel DT; Leeder JS; Gaedigk A
Drug Metab Dispos; 2002 May; 30(5):595-601. PubMed ID: 11950793
[TBL] [Abstract][Full Text] [Related]
13. Quantitation of human cytochrome P450 2D6 protein with immunoblot and mass spectrometry analysis.
Yu AM; Qu J; Felmlee MA; Cao J; Jiang XL
Drug Metab Dispos; 2009 Jan; 37(1):170-7. PubMed ID: 18832475
[TBL] [Abstract][Full Text] [Related]
14. Reduced (+/-)-3,4-methylenedioxymethamphetamine ("Ecstasy") metabolism with cytochrome P450 2D6 inhibitors and pharmacogenetic variants in vitro.
Ramamoorthy Y; Yu AM; Suh N; Haining RL; Tyndale RF; Sellers EM
Biochem Pharmacol; 2002 Jun; 63(12):2111-9. PubMed ID: 12110370
[TBL] [Abstract][Full Text] [Related]
15. Influence of phenylalanine-481 substitutions on the catalytic activity of cytochrome P450 2D6.
Hayhurst GP; Harlow J; Chowdry J; Gross E; Hilton E; Lennard MS; Tucker GT; Ellis SW
Biochem J; 2001 Apr; 355(Pt 2):373-9. PubMed ID: 11284724
[TBL] [Abstract][Full Text] [Related]
16. Effects of monoamine oxidase inhibitor and cytochrome P450 2D6 status on 5-methoxy-N,N-dimethyltryptamine metabolism and pharmacokinetics.
Shen HW; Wu C; Jiang XL; Yu AM
Biochem Pharmacol; 2010 Jul; 80(1):122-8. PubMed ID: 20206139
[TBL] [Abstract][Full Text] [Related]
17. Stable expression of human cytochrome P450 2D6*10 in HepG2 cells.
Zhuge J; Yu YN; Wu XD
World J Gastroenterol; 2004 Jan; 10(2):234-7. PubMed ID: 14716830
[TBL] [Abstract][Full Text] [Related]
18. The molecular and enzyme kinetic basis for the diminished activity of the cytochrome P450 2D6.17 (CYP2D6.17) variant. Potential implications for CYP2D6 phenotyping studies and the clinical use of CYP2D6 substrate drugs in some African populations.
Bapiro TE; Hasler JA; Ridderström M; Masimirembwa CM
Biochem Pharmacol; 2002 Nov; 64(9):1387-98. PubMed ID: 12392820
[TBL] [Abstract][Full Text] [Related]
19. Inhibition kinetics of monoclonal antibodies against cytochromes P450.
Mei Q; Tang C; Lin Y; Rushmore TH; Shou M
Drug Metab Dispos; 2002 Jun; 30(6):701-8. PubMed ID: 12019198
[TBL] [Abstract][Full Text] [Related]
20. In silico study on the inhibitory interaction of drugs with wild-type CYP2D6.1 and the natural variant CYP2D6.17.
Handa K; Nakagome I; Yamaotsu N; Gouda H; Hirono S
Drug Metab Pharmacokinet; 2014; 29(1):52-60. PubMed ID: 23857029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
